AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02318238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 meters gait speed
Study NCT04290975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-shifting of follow-up care for pediatric epilepsy
Description: For the intervention arm, follow-up care of children with epilepsy will be shifted to be performed primarily by Community Health Workers (CHWs) with specialized epilepsy training
Study NCT04290975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care for pediatric epilepsy
Description: For the intervention arm, follow-up care of children with epilepsy will be performed primarily by physicians, with CHWs serving to collect standardized data regarding outcomes
Study NCT01697475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational text messaging
Description: Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
Study NCT01687751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse
Study NCT00185445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate (Fludara)
Description: All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
Study NCT03717025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SUCTION BLISTER EPIDERMAL GRAFTING
Description: 1. Preferred donor sites for making blister is lateral aspect of upper thigh. The area is shaved and cleansed with surgical spirit.~2. Blister formation is induced by using suction apparatus.~3. Recipient site is surgically prepared by doing dermabrasion.~4. After formation of blisters, each blister is gently cleansed with normal saline and cut all along its border with curved iris scissors parallel to the skin surface. The roof is everted over the thumb with dermal surface facing upwards and then with the help of blunt end of forceps it is placed on the recipient area.~5. The graft is firmly pressed with sterile moist gauze to remove any underneath serous collection.~6. The pressure dressing is done with double layer framycetin tulle, moist gauze and bandage.~7. Donor area is dressed with dry sterile pads.~8. The part is immobilized and Antibiotics and Analgesic are given till dressing are removed (after 5-7 days).
Study NCT02554201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical pudendal nerve stimulation
Description: Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. Needles of 0.40 Х 100 mm are inserted perpendicularly to the upper points to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The two lower points are about 1 cm bilateral to the tip of the coccyx. Needles of 0.40 Х 100 or 125 mm are inserted obliquely to the lower points towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally needles.
Study NCT03624335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECC
Description: Early clamping of the umbilical cord
Study NCT02554201 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal electrical stimulation
Description: A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
Study NCT02734849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK001 low dose
Description: 25 mg AK001 will be administered as multiple doses
Study NCT02734849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK001 high dose
Description: 250 mg AK001 will be administered as multiple doses
Study NCT02734849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as multiple doses
Study NCT02056249 — intervention group
Intervention type: OTHER
Intervention: Norepinephrine Transporter (NET) ligand
Description: Norepinephrine Transporter (NET) ligand for iv administration during Positron Emission Tomography scan to measure changes in brain NET concentration based on insulin levels.
Study NCT03810261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oil-based vitamin D
Description: Participants will receive oil-based VALENS vitamin D, 1000 IU/day for 8 weeks.
Study NCT03810261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water-based vitamin D
Description: Participants will receive water-based VALENS vitamin D, 1000 IU/day for 8 weeks.
Study NCT03624335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCC
Description: Delayed clamping of the umbilical cord
Study NCT03624335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test 6hours
Description: Blood Test 6hours
Study NCT03624335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test 24hours
Description: Blood Test 24hours
Study NCT03624335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test 48hours
Description: Blood Test 48hours
Study NCT03624335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test 28days
Description: Blood Test 28days
Study NCT00640588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: Arm 1: 600 mg/day, oral telbivudina for 24 weeks
Study NCT00640588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral adefovir
Description: Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
Study NCT01615770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy
Description: At each clinic session, staff met with participants individually for 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. Those participants randomized to extended CBT continued to work with treatment staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions, lasting approximately 30 minutes, were conducted at the San Jose clinic site at weeks 8, 12, 16 and 20.
Study NCT03810261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D capsules
Description: Participants will receive vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks.
Study NCT03229876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-UCART
Description: A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
Study NCT01594463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound examination
Description: ultrasound examination between week 30+1 weeks to 31+6 weeks
Study NCT01594463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound examination
Description: ultrasound examination between 34+1 weeks to 35+6 weeks
Study NCT03986476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 5x10\^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks
Study NCT03986476 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
Study NCT02484599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized attention training (CAT)
Description: Three sessions of active computerized attention training.
Study NCT02484599 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham computerized attention training (control condition)
Description: Three sessions of sham computerized attention training.
Study NCT03432338 — intervention group
Intervention type: OTHER
Intervention: inquiries
Description: Inquires reported to clinician.
Study NCT02724579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02724579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02724579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02724579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given PO
Study NCT02724579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02724579 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo craniospinal radiation therapy
Study NCT02724579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV or via minibag
Study NCT02724579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV or via minibag
Study NCT00758368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine
Description: Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
Study NCT00758368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine
Description: Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
Study NCT02923830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heparinized saline catheter flush
Description: The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
Study NCT02923830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline-only catheter flush
Description: The intervention group will have their port catheters flushed with saline only.
Study NCT00623233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 2500 mg/m\^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
Study NCT00623233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event \[AE\], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)~Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity.
Study NCT02414607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elderberry Juice
Study NCT02414607 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03717025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MINI PUNCH GRAFTING
Description: 1. Recipient area is prepared first after shaving and cleaning with surgical spirit. 2 % lignocaine with or without adrenalin will be infiltrated as local aneasthetic.~2. The punched out chambers are spaced at a gap of less than 5 mm (preferably 2 - 2.5 mm) from each other.~3. The donor area is either upper lateral portion of thigh or gluteal region.~4. Grafts are placed directly from donor to the recipient area. Care is taken, so that graft edges are not folded, the tissue is not crushed or placed upside down.~5. Hemostasis is achieved by pressing a saline soaked gauze piece over the area.~6. For the recipient area 3 layers of dressing from inside out are : paraffin embedded non adherent sterile gauze, sterile surgipad, and micropore.~7. For the donor area only surgipad and micropore are used.~8. Immobilisation of recipient area is advised along with antibiotics and analgesics till removal of dressing (after 4-7 days).
Study NCT03717025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NON CULTURED EPIDERMAL CELL SUSPENSION
Description: 1. About one-tenth the size of recipient area is selected as the donor site.~2. Split thickness skin graft is taken under aseptic precautions with the help of a shaving blade held firmly by a straight artery forceps.~3. The area is dressed with Bactigras gauze.~4. Split thickness skin specimen is transferred under aseptic conditions to a container with Normal Saline and transferred to laboratory for preparing suspension.~5. Recipient site is dermabraded under aseptic precautions until tiny pinpoint bleeding spots are seen.~6. Epidermal cell suspension is carefully transferred to a tuberculin syringe.~7. With 18 gauge needle attached to this syringe, suspension is spread evenly on dermabraded recipient site.~8. This is then covered with Collagen dressing, followed by bactigras, guaze and tegaderm dressings from inside to outside.~9. The patient is observed for 2 hours after performing the procedure and given antibiotics and analgesics for 5-7 days till dressing removal.
Study NCT02927366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QCC374
Description: 0.03 mg (2 capsules of 0.015 mg) BID 0.06 mg (1 capsule of 0.06 mg) BID 0.12 mg (2 capsules of 0.06 mg) BID
Study NCT02927366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matching
Description: Placebo matching to QCC374:~0.03 mg BID, 0.06 mg BID and 0.12 mg BID
Study NCT04588220 — intervention group
Intervention type: OTHER
Intervention: Obstetric ultrasound and fetal-maternal assessment
Description: melatonin, soluble urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements
Study NCT04789954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eptacog alfa, activated
Description: A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.
Study NCT03278392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Description: Task instructions provided to subject (5mins), subject prepares speech on their strengths and weaknesses (5 mins), subject delivers speech before a stern evaluative committee while being video-taped (5 mins), subject completes a mental arithmetic challenge task before the evaluative committee with critiques if errors are made (5mins).
Study NCT03278392 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Placebo Non-stress task
Description: Subject engages in a friendly conversation about a neutral or happy topic (e.g. recent holiday, favorite past-times) for 15 minutes with a familiar research staff member.
Study NCT01548118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16/18 vaccine, 0,5ml
Description: Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
Study NCT01548118 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control, 0.5ml
Description: Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
Study NCT01548118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16/18 vaccine, 1.0ml
Description: Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
Study NCT01548118 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control, 1.0ml
Description: Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
Study NCT02974179 — intervention group
Intervention type: BIOLOGICAL
Intervention: Subjects from Study AG-CLI-0206 who received AMG0001
Description: Subjects from Study AG-CLI-0206 who received the study product AMG0001
Study NCT02474875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: Patients in experimental groups will receive different educational sessions (contents and duration)
Study NCT02474875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: Patients in experimental groups will receive different educational sessions (contents and duration)
Study NCT01624792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Dose: 7.0 g/day (= 7 capsules/day).
Study NCT01624792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).
Study NCT01624792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil and placebo
Description: Dose: 7.0 g/day (= 4 capsules/day fish oil = 2.0g EPA+DHA/day and 3 capsules/day olive oil).
Study NCT03972735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric interview
Description: PANSS, MADRS, PSP, YMRS
Study NCT04789954 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eptacog alfa, activated
Description: A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.
Study NCT02388165 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine
Description: SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
Study NCT00510120 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent management training (PMT)
Description: PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.
Study NCT00510120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative problem solving (CPS)
Description: CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
Study NCT04210232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECNIS® TORIC II Intraocular Lens (IOL)
Description: Surgeons will perform standardized, small-incision, cataract surgery and implant in one or both eyes the study lenses.
Study NCT02658149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine with NaCl
Description: 50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment
Study NCT02658149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 0.15 mg Epinephrine are injected as part of the drug cocktail
Study NCT02658149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 4 mg Morphine are injected as part of the drug cocktail
Study NCT02658149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: 30 mg morphine are injected as part of the drug cocktail
Study NCT02658149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30 mL 0.5% Ropivicaine are injected as part of the drug cocktail
Study NCT03880123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor will be taken orally on Days 1, 8, 15, and 22 of each cycle at the following dose levels (DLs):~DL 1: 40 mg; DL 2: 60 mg; DL 3: 80 mg; DL 4: 100 mg~The selinexor product is provided as 20 mg tablets in wallet-sized blister packs. Selinexor should be taken together with ixazomib.